The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.

"The colchicine dosage schedule will vary according to the following scenarios:~1. In patients not receiving Lopinavir/Ritonavir~ * Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)~ * The next day 0.5 mg bid for 14 days or until discharge.~2. In patients receiving Lopinavir/Ritonavir~ * Loading dose of 0.5 mg (day 1)~ * After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.~3. Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir~ * Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.~ * Continue with 0.5 mg every 72 hours for 14 days or until discharge.~Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube."

Local standard of care for COVID-19 SARS moderate /high-risk patients